請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5000
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蔡錦華(Ching- Hwa Tsai) | |
dc.contributor.author | Pei-Yi Lin | en |
dc.contributor.author | 林佩頤 | zh_TW |
dc.date.accessioned | 2021-05-15T17:50:51Z | - |
dc.date.available | 2017-10-09 | |
dc.date.available | 2021-05-15T17:50:51Z | - |
dc.date.copyright | 2014-10-09 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-19 | |
dc.identifier.citation | 1. Adamson, A.L., Darr, D., Holley-Guthrie, E., Johnson, R.A., Mauser, A., Swenson, J., and Kenney, S. (2000). Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. Journal of virology 74, 1224-1233.
2. Ahn, N.G., Seger, R., Bratlien, R.L., Diltz, C.D., Tonks, N.K., and Krebs, E.G. (1991). Multiple components in an epidermal growth factor-stimulated protein kinase cascade. In vitro activation of a myelin basic protein/microtubule-associated protein 2 kinase. The Journal of biological chemistry 266, 4220-4227. 3. Anderson, L.J., and Longnecker, R. (2008). EBV LMP2A provides a surrogate pre-B cell receptor signal through constitutive activation of the ERK/MAPK pathway. The Journal of general virology 89, 1563-1568. 4. Arkell, R.S., Dickinson, R.J., Squires, M., Hayat, S., Keyse, S.M., and Cook, S.J. (2008). DUSP6/MKP-3 inactivates ERK1/2 but fails to bind and inactivate ERK5. Cellular signalling 20, 836-843. 5. Avruch, J. (2007). MAP kinase pathways: the first twenty years. Biochimica et biophysica acta 1773, 1150-1160. 6. Babcock, G.J., Decker, L.L., Volk, M., and Thorley-Lawson, D.A. (1998). EBV persistence in memory B cells in vivo. Immunity 9, 395-404. 7. Baik, S.Y., Yun, H.S., Lee, H.J., Lee, M.H., Jung, S.E., Kim, J.W., Jeon, J.P., Shin, Y.K., Rhee, H.S., Kimm, K.C., et al. (2007). Identification of stathmin 1 expression induced by Epstein-Barr virus in human B lymphocytes. Cell proliferation 40, 268-281. 8. Bellon, S., Fitzgibbon, M.J., Fox, T., Hsiao, H.M., and Wilson, K.P. (1999). The structure of phosphorylated p38gamma is monomeric and reveals a conserved activation-loop conformation. Structure 7, 1057-1065. 9. Bermudez, O., Marchetti, S., Pages, G., and Gimond, C. (2008). Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway. Oncogene 27, 3685-3691. 10. Bermudez, O., Pages, G., and Gimond, C. (2010). The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. American journal of physiology Cell physiology 299, C189-202. 11. Borza, C.M., and Hutt-Fletcher, L.M. (2002). Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nature medicine 8, 594-599. 12. Boutros, T., Chevet, E., and Metrakos, P. (2008). Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacological reviews 60, 261-310. 13. Brondello, J.M., Brunet, A., Pouyssegur, J., and McKenzie, F.R. (1997). The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. The Journal of biological chemistry 272, 1368-1376. 14. Brunet, A., Roux, D., Lenormand, P., Dowd, S., Keyse, S., and Pouyssegur, J. (1999). Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. The EMBO journal 18, 664-674. 15. Canagarajah, B.J., Khokhlatchev, A., Cobb, M.H., and Goldsmith, E.J. (1997). Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell 90, 859-869. 16. Cejudo-Marin, R., Tarrega, C., Nunes-Xavier, C.E., and Pulido, R. (2012). Caspase-3 cleavage of DUSP6/MKP3 at the interdomain region generates active MKP3 fragments that regulate ERK1/2 subcellular localization and function. Journal of molecular biology 420, 128-138. 17. Chang, Y., Lee, H.H., Chang, S.S., Hsu, T.Y., Wang, P.W., Chang, Y.S., Takada, K., and Tsai, C.H. (2004). Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta. Journal of virology 78, 13028-13036. 18. Chang, Y., Lee, H.H., Chen, Y.T., Lu, J., Wu, S.Y., Chen, C.W., Takada, K., and Tsai, C.H. (2006). Induction of the early growth response 1 gene by Epstein-Barr virus lytic transactivator Zta. Journal of virology 80, 7748-7755. 19. Chen, S.Y., Lu, J., Shih, Y.C., and Tsai, C.H. (2002). Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase. Journal of virology 76, 9556-9561. 20. Chen, X., Liang, S., Zheng, W., Liao, Z., Shang, T., and Ma, W. (2008). Meta-analysis of nasopharyngeal carcinoma microarray data explores mechanism of EBV-regulated neoplastic transformation. BMC genomics 9, 322. 21. Chen, Y.R., Shrivastava, A., and Tan, T.H. (2001). Down-regulation of the c-Jun N-terminal kinase (JNK) phosphatase M3/6 and activation of JNK by hydrogen peroxide and pyrrolidine dithiocarbamate. Oncogene 20, 367-374. 22. Cotsiki, M., Oehrl, W., Samiotaki, M., Theodosiou, A., and Panayotou, G. (2012). Phosphorylation of the M3/6 dual-specificity phosphatase enhances the activation of JNK by arsenite. Cellular signalling 24, 664-676. 23. Countryman, J., and Miller, G. (1985). Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proceedings of the National Academy of Sciences of the United States of America 82, 4085-4089. 24. Cuadrado, A., and Nebreda, A.R. (2010). Mechanisms and functions of p38 MAPK signalling. The Biochemical journal 429, 403-417. 25. Dawson, C.W., Laverick, L., Morris, M.A., Tramoutanis, G., and Young, L.S. (2008). Epstein-Barr virus-encoded LMP1 regulates epithelial cell motility and invasion via the ERK-MAPK pathway. Journal of virology 82, 3654-3664. 26. Dhillon, A.S., Hagan, S., Rath, O., and Kolch, W. (2007). MAP kinase signalling pathways in cancer. Oncogene 26, 3279-3290. 27. Dickinson, R.J., and Keyse, S.M. (2006). Diverse physiological functions for dual-specificity MAP kinase phosphatases. Journal of cell science 119, 4607-4615. 28. Ebell, M.H. (2004). Epstein-Barr virus infectious mononucleosis. American family physician 70, 1279-1287. 29. Eliopoulos, A.G., Gallagher, N.J., Blake, S.M., Dawson, C.W., and Young, L.S. (1999). Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. The Journal of biological chemistry 274, 16085-16096. 30. Eliopoulos, A.G., and Young, L.S. (2001). LMP1 structure and signal transduction. Seminars in cancer biology 11, 435-444. 31. Epstein, M.A., Achong, B.G., and Barr, Y.M. (1964). Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma. Lancet 1, 702-703. 32. Evan, G.I., Lewis, G.K., Ramsay, G., and Bishop, J.M. (1985). Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Molecular and cellular biology 5, 3610-3616. 33. Farooq, A., and Zhou, M.M. (2004). Structure and regulation of MAPK phosphatases. Cellular signalling 16, 769-779. 34. Fenton, M., and Sinclair, A.J. (1999). Divergent requirements for the MAPK(ERK) signal transduction pathway during initial virus infection of quiescent primary B cells and disruption of Epstein-Barr virus latency by phorbol esters. Journal of virology 73, 8913-8916. 35. Fernandez-Medarde, A., and Santos, E. (2011). Ras in cancer and developmental diseases. Genes & cancer 2, 344-358. 36. Freshney, N.W., Rawlinson, L., Guesdon, F., Jones, E., Cowley, S., Hsuan, J., and Saklatvala, J. (1994). Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 78, 1039-1049. 37. Furukawa, T., Sunamura, M., Motoi, F., Matsuno, S., and Horii, A. (2003). Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. The American journal of pathology 162, 1807-1815. 38. Gires, O., Zimber-Strobl, U., Gonnella, R., Ueffing, M., Marschall, G., Zeidler, R., Pich, D., and Hammerschmidt, W. (1997). Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. The EMBO journal 16, 6131-6140. 39. Greenspan, J.S., Greenspan, D., Lennette, E.T., Abrams, D.I., Conant, M.A., Petersen, V., and Freese, U.K. (1985). Replication of Epstein-Barr virus within the epithelial cells of oral 'hairy' leukoplakia, an AIDS-associated lesion. The New England journal of medicine 313, 1564-1571. 40. Guan, K.L., Broyles, S.S., and Dixon, J.E. (1991). A Tyr/Ser protein phosphatase encoded by vaccinia virus. Nature 350, 359-362. 41. Hammerschmidt, W., and Sugden, B. (1988). Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell 55, 427-433. 42. Hardwick, J.M., Lieberman, P.M., and Hayward, S.D. (1988). A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. Journal of virology 62, 2274-2284. 43. Hennessy, K., Fennewald, S., Hummel, M., Cole, T., and Kieff, E. (1984). A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proceedings of the National Academy of Sciences of the United States of America 81, 7207-7211. 44. Hsu, T.Y., Chang, Y., Wang, P.W., Liu, M.Y., Chen, M.R., Chen, J.Y., and Tsai, C.H. (2005). Reactivation of Epstein-Barr virus can be triggered by an Rta protein mutated at the nuclear localization signal. The Journal of general virology 86, 317-322. 45. Huang, C.Y., and Tan, T.H. (2012). DUSPs, to MAP kinases and beyond. Cell & bioscience 2, 24. 46. Jeffrey, K.L., Camps, M., Rommel, C., and Mackay, C.R. (2007). Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nature reviews Drug discovery 6, 391-403. 47. Johansson, B., Klein, G., Henle, W., and Henle, G. (1970). Epstein-Barr virus (EBV)-associated antibody patterns in malignant lymphoma and leukemia. I. Hodgkin's disease. International journal of cancer Journal international du cancer 6, 450-462. 48. Johnson, G.L., and Lapadat, R. (2002). Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911-1912. 49. Jones, J.F., Shurin, S., Abramowsky, C., Tubbs, R.R., Sciotto, C.G., Wahl, R., Sands, J., Gottman, D., Katz, B.Z., and Sklar, J. (1988). T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. The New England journal of medicine 318, 733-741. 50. Joseph, A.M., Babcock, G.J., and Thorley-Lawson, D.A. (2000). Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. Journal of virology 74, 9964-9971. 51. Jurek, A., Amagasaki, K., Gembarska, A., Heldin, C.H., and Lennartsson, J. (2009). Negative and positive regulation of MAPK phosphatase 3 controls platelet-derived growth factor-induced Erk activation. The Journal of biological chemistry 284, 4626-4634. 52. Karlsson, M., Mathers, J., Dickinson, R.J., Mandl, M., and Keyse, S.M. (2004). Both nuclear-cytoplasmic shuttling of the dual specificity phosphatase MKP-3 and its ability to anchor MAP kinase in the cytoplasm are mediated by a conserved nuclear export signal. The Journal of biological chemistry 279, 41882-41891. 53. Kennedy, N.J., and Davis, R.J. (2003). Role of JNK in tumor development. Cell cycle 2, 199-201. 54. Kennedy, N.J., Sluss, H.K., Jones, S.N., Bar-Sagi, D., Flavell, R.A., and Davis, R.J. (2003). Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes & development 17, 629-637. 55. Keuling, A.M., Andrew, S.E., and Tron, V.A. (2010). Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: novel regulation of PUMA. Pigment cell & melanoma research 23, 430-440. 56. Kieser, A., Kilger, E., Gires, O., Ueffing, M., Kolch, W., and Hammerschmidt, W. (1997). Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. The EMBO journal 16, 6478-6485. 57. Kinney, C.M., Chandrasekharan, U.M., Yang, L., Shen, J., Kinter, M., McDermott, M.S., and DiCorleto, P.E. (2009). Histone H3 as a novel substrate for MAP kinase phosphatase-1. American journal of physiology Cell physiology 296, C242-249. 58. Klein, G., Giovanella, B., Westman, A., Stehlin, J.S., and Mumford, D. (1975). An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 5, 319-334. 59. Kolch, W. (2000). Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. The Biochemical journal 351 Pt 2, 289-305. 60. Kultz, D. (1998). Phylogenetic and functional classification of mitogen- and stress-activated protein kinases. Journal of molecular evolution 46, 571-588. 61. Kwak, S.P., Hakes, D.J., Martell, K.J., and Dixon, J.E. (1994). Isolation and characterization of a human dual specificity protein-tyrosine phosphatase gene. The Journal of biological chemistry 269, 3596-3604. 62. Lang, R., Hammer, M., and Mages, J. (2006). DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J Immunol 177, 7497-7504. 63. Li, M., Zhou, J.Y., Ge, Y., Matherly, L.H., and Wu, G.S. (2003). The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. The Journal of biological chemistry 278, 41059-41068. 64. Liu, K., Lemon, B., and Traktman, P. (1995). The dual-specificity phosphatase encoded by vaccinia virus, VH1, is essential for viral transcription in vivo and in vitro. Journal of virology 69, 7823-7834. 65. Liu, Y., Shepherd, E.G., and Nelin, L.D. (2007). MAPK phosphatases--regulating the immune response. Nature reviews Immunology 7, 202-212. 66. Ma, J., Yu, X., Guo, L., and Lu, S.H. (2013). DUSP6, a tumor suppressor, is involved in differentiation and apoptosis in esophageal squamous cell carcinoma. Oncology letters 6, 1624-1630. 67. Macsween, K.F., and Crawford, D.H. (2003). Epstein-Barr virus-recent advances. The Lancet infectious diseases 3, 131-140. 68. Marchetti, S., Gimond, C., Chambard, J.C., Touboul, T., Roux, D., Pouyssegur, J., and Pages, G. (2005). Extracellular signal-regulated kinases phosphorylate mitogen-activated protein kinase phosphatase 3/DUSP6 at serines 159 and 197, two sites critical for its proteasomal degradation. Molecular and cellular biology 25, 854-864. 69. Martell, K.J., Seasholtz, A.F., Kwak, S.P., Clemens, K.K., and Dixon, J.E. (1995). hVH-5: a protein tyrosine phosphatase abundant in brain that inactivates mitogen-activated protein kinase. Journal of neurochemistry 65, 1823-1833. 70. Menezes, J., Leibold, W., Klein, G., and Clements, G. (1975). Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine / [publiee pour l'AAICIG] 22, 276-284. 71. Morrison, D.J., Kim, M.K., Berkofsky-Fessler, W., and Licht, J.D. (2008). WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression. Molecular cancer research : MCR 6, 1225-1231. 72. Mosialos, G., Birkenbach, M., Yalamanchili, R., VanArsdale, T., Ware, C., and Kieff, E. (1995). The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80, 389-399. 73. Nemerow, G.R., Mold, C., Schwend, V.K., Tollefson, V., and Cooper, N.R. (1987). Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. Journal of virology 61, 1416-1420. 74. Nishina, H., Wada, T., and Katada, T. (2004). Physiological roles of SAPK/JNK signaling pathway. Journal of biochemistry 136, 123-126. 75. Noguchi, T., Metz, R., Chen, L., Mattei, M.G., Carrasco, D., and Bravo, R. (1993). Structure, mapping, and expression of erp, a growth factor-inducible gene encoding a nontransmembrane protein tyrosine phosphatase, and effect of ERP on cell growth. Molecular and cellular biology 13, 5195-5205. 76. Oehrl, W., Cotsiki, M., and Panayotou, G. (2013). Differential regulation of M3/6 (DUSP8) signaling complexes in response to arsenite-induced oxidative stress. Cellular signalling 25, 429-438. 77. Palacios, C., Collins, M.K., and Perkins, G.R. (2001). The JNK phosphatase M3/6 is inhibited by protein-damaging stress. Current biology : CB 11, 1439-1443. 78. Pallesen, G., Hamilton-Dutoit, S.J., Rowe, M., and Young, L.S. (1991). Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 337, 320-322. 79. Patterson, K.I., Brummer, T., O'Brien, P.M., and Daly, R.J. (2009). Dual-specificity phosphatases: critical regulators with diverse cellular targets. The Biochemical journal 418, 475-489. 80. Payne, D.M., Rossomando, A.J., Martino, P., Erickson, A.K., Her, J.H., Shabanowitz, J., Hunt, D.F., Weber, M.J., and Sturgill, T.W. (1991). Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). The EMBO journal 10, 885-892. 81. Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.E., Karandikar, M., Berman, K., and Cobb, M.H. (2001). Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocrine reviews 22, 153-183. 82. Pope, J.H., Horne, M.K., and Scott, W. (1968). Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. International journal of cancer Journal international du cancer 3, 857-866. 83. Qin, Z., Dai, L., Defee, M., Findlay, V.J., Watson, D.K., Toole, B.P., Cameron, J., Peruzzi, F., Kirkwood, K., and Parsons, C. (2013). Kaposi's sarcoma-associated herpesvirus suppression of DUSP1 facilitates cellular pathogenesis following de novo infection. Journal of virology 87, 621-635. 84. Robbins, D.J., Zhen, E., Owaki, H., Vanderbilt, C.A., Ebert, D., Geppert, T.D., and Cobb, M.H. (1993). Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro. The Journal of biological chemistry 268, 5097-5106. 85. Ryser, S., Massiha, A., Piuz, I., and Schlegel, W. (2004). Stimulated initiation of mitogen-activated protein kinase phosphatase-1 (MKP-1) gene transcription involves the synergistic action of multiple cis-acting elements in the proximal promoter. The Biochemical journal 378, 473-484. 86. Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989). Molecular cloning : a laboratory manual (Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory). 87. Satoh, T., Fukuda, M., and Sairenji, T. (2002). Distinct patterns of mitogen-activated protein kinase phosphorylation and Epstein-Barr virus gene expression in Burkitt's lymphoma cell lines versus B lymphoblastoid cell lines. Virus genes 25, 15-21. 88. Schultheiss, U., Puschner, S., Kremmer, E., Mak, T.W., Engelmann, H., Hammerschmidt, W., and Kieser, A. (2001). TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. The EMBO journal 20, 5678-5691. 89. Schuster, V., and Kreth, H.W. (1992). Epstein-Barr virus infection and associated diseases in children. I. Pathogenesis, epidemiology and clinical aspects. European journal of pediatrics 151, 718-725. 90. Shen, W.H., Wang, J., Wu, J., Zhurkin, V.B., and Yin, Y. (2006). Mitogen-activated protein kinase phosphatase 2: a novel transcription target of p53 in apoptosis. Cancer research 66, 6033-6039. 91. Shimizu, N., Tanabe-Tochikura, A., Kuroiwa, Y., and Takada, K. (1994). Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. Journal of virology 68, 6069-6073. 92. Siouda, M., Frecha, C., Accardi, R., Yue, J., Cuenin, C., Gruffat, H., Manet, E., Herceg, Z., Sylla, B.S., and Tommasino, M. (2014). Epstein-Barr virus down-regulates tumor suppressor DOK1 expression. PLoS pathogens 10, e1004125. 93. Sixbey, J.W., Vesterinen, E.H., Nedrud, J.G., Raab-Traub, N., Walton, L.A., and Pagano, J.S. (1983). Replication of Epstein-Barr virus in human epithelial cells infected in vitro. Nature 306, 480-483. 94. Theodosiou, A., and Ashworth, A. (2002). Differential effects of stress stimuli on a JNK-inactivating phosphatase. Oncogene 21, 2387-2397. 95. Theodosiou, A.M., Rodrigues, N.R., Nesbit, M.A., Ambrose, H.J., Paterson, H., McLellan-Arnold, E., Boyd, Y., Leversha, M.A., Owen, N., Blake, D.J., et al. (1996). A member of the MAP kinase phosphatase gene family in mouse containing a complex trinucleotide repeat in the coding region. Human molecular genetics 5, 675-684. 96. Tournier, C., Hess, P., Yang, D.D., Xu, J., Turner, T.K., Nimnual, A., Bar-Sagi, D., Jones, S.N., Flavell, R.A., and Davis, R.J. (2000). Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 288, 870-874. 97. Tsai, C.H., Liu, M.T., Chen, M.R., Lu, J., Yang, H.L., Chen, J.Y., and Yang, C.S. (1997). Characterization of Monoclonal Antibodies to the Zta and DNase Proteins of Epstein-Barr Virus. Journal of biomedical science 4, 69-77. 98. Tsai, C.L., Li, H.P., Lu, Y.J., Hsueh, C., Liang, Y., Chen, C.L., Tsao, S.W., Tse, K.P., Yu, J.S., and Chang, Y.S. (2006). Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. Cancer research 66, 11668-11676. 99. Tsai, C.N., Tsai, C.L., Tse, K.P., Chang, H.Y., and Chang, Y.S. (2002). The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proceedings of the National Academy of Sciences of the United States of America 99, 10084-10089. 100. Tsao, S.W., Tramoutanis, G., Dawson, C.W., Lo, A.K., and Huang, D.P. (2002). The significance of LMP1 expression in nasopharyngeal carcinoma. Seminars in cancer biology 12, 473-487. 101. Ueda, K., Arakawa, H., and Nakamura, Y. (2003). Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53. Oncogene 22, 5586-5591. 102. van Huijsduijnen, R.H., Guy, R.K., Chibale, K., Haynes, R.K., Peitz, I., Kelter, G., Phillips, M.A., Vennerstrom, J.L., Yuthavong, Y., and Wells, T.N. (2013). Anticancer properties of distinct antimalarial drug classes. PloS one 8, e82962. 103. Weston, C.R., and Davis, R.J. (2002). The JNK signal transduction pathway. Current opinion in genetics & development 12, 14-21. 104. Wishart, M.J., and Dixon, J.E. (1998). Gathering STYX: phosphatase-like form predicts functions for unique protein-interaction domains. Trends in biochemical sciences 23, 301-306. 105. Wong, V.C., Chen, H., Ko, J.M., Chan, K.W., Chan, Y.P., Law, S., Chua, D., Kwong, D.L., Lung, H.L., Srivastava, G., et al. (2012). Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. International journal of cancer Journal international du cancer 130, 83-95. 106. Yao, Q.Y., Rickinson, A.B., and Epstein, M.A. (1985). A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. International journal of cancer Journal international du cancer 35, 35-42. 107. Yates, J.L., Warren, N., and Sugden, B. (1985). Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313, 812-815. 108. Yi, H., Morton, C.C., Weremowicz, S., McBride, O.W., and Kelly, K. (1995). Genomic organization and chromosomal localization of the DUSP2 gene, encoding a MAP kinase phosphatase, to human 2p11.2-q11. Genomics 28, 92-96. 109. Yin, Y., Liu, Y.X., Jin, Y.J., Hall, E.J., and Barrett, J.C. (2003). PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature 422, 527-531. 110. Young, L.S., and Rickinson, A.B. (2004). Epstein-Barr virus: 40 years on. Nature reviews Cancer 4, 757-768. 111. Zarubin, T., and Han, J. (2005). Activation and signaling of the p38 MAP kinase pathway. Cell research 15, 11-18. 112. Zhang, T., Choy, M., Jo, M., and Roberson, M.S. (2001). Structural organization of the rat mitogen-activated protein kinase phosphatase 2 gene. Gene 273, 71-79. 113. Zhang, Z., Kobayashi, S., Borczuk, A.C., Leidner, R.S., Laframboise, T., Levine, A.D., and Halmos, B. (2010). Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 31, 577-586. 114. Zhou, G., Bao, Z.Q., and Dixon, J.E. (1995). Components of a new human protein kinase signal transduction pathway. The Journal of biological chemistry 270, 12665-12669. 115. Zhu, Q.Y., Liu, Q., Chen, J.X., Lan, K., and Ge, B.X. (2010). MicroRNA-101 targets MAPK phosphatase-1 to regulate the activation of MAPKs in macrophages. J Immunol 185, 7435-7442. 116. Ziegler, J.L., Drew, W.L., Miner, R.C., Mintz, L., Rosenbaum, E., Gershow, J., Lennette, E.T., Greenspan, J., Shillitoe, E., Beckstead, J., et al. (1982). Outbreak of Burkitt's-like lymphoma in homosexual men. Lancet 2, 631-633. 117. zur Hausen, H., Schulte-Holthausen, H., Klein, G., Henle, W., Henle, G., Clifford, P., and Santesson, L. (1970). EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228, 1056-1058. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/5000 | - |
dc.description.abstract | EB病毒(Epstein-Barr virus)屬於疱疹病毒家族的一員,是第一個由WHO組織認證為與腫瘤高度相關的DNA病毒。在體外實驗,具有能夠將B細胞不朽化(Immortalize),使其成為不斷增生的淋巴母芽細胞株(Lymphoblastic cell line, LCLs)。文獻指出EB病毒與許多人類惡性腫瘤有高度相關,如巴氏淋巴瘤(Burkitt’s lymphoma)、霍金氏淋巴瘤(Hodgkin’s lymphoma)、移植後淋巴增生疾病(Post-transplant lymphoproliferative disorder, PTLD)、鼻咽癌(nasopharyngeal carcinoma, NPC)等。
EB病毒為了長期存活於宿主細胞內,會抑制細胞凋亡因子,並且持續性活化利於生長之訊息傳遞路徑,例如NF-kB、ERK、JNK、p38、Akt。最重要地,EB病毒藉由調控宿主免疫反應,使得EB病毒得以逃避免疫攻擊,穩定存活於細胞內。本實驗室先前利用cDNA微陣列實驗,分析CD19+初級B細胞(primary B cells)及LCLs,探查兩者細胞內基因表現之變化情形。發現EB病毒感染B細胞後,影響B細胞內多種雙特異性磷酸酶(Dual specificity phosphatase, DUSPs)之基因表現,如DUSP1、DUSP2、DUSP6、DUSP8。DUSP於細胞內主要使特定目標之MAPK去磷酸化,使MAPK活性降低,扮演負向調控角色。其中,DUSP6及DUSP8分別可調控ERK或JNK/p38之磷酸化程度。因此,我們想了解MAPK之表現與調控對EB病毒在不朽化B細胞之過程有何影響。根據DUSPs對於下游目標MAPK專一性,我們選擇其中13種DUSPs,利用RT-PCR分析CD19+初級B細胞及相配對之LCLs細胞,發現當B細胞受到EB病毒感染時DUSP1、DUSP2、DUSP6、DUSP8表現量明顯受到抑制。同樣地利用西方墨點法也觀察到DUSP6及DUSP8蛋白質表現量下降。進一步確認上述現象,以四個來源之初級B細胞及相對應LCLs觀察到DUSP6及DUSP8蛋白質表現量有相同趨勢。 下一步,我們欲探查EB病毒透過何種病毒基因抑制DUSP6及DUSP8基因表現。由慢病毒感染細胞株Akata及BJAB之實驗中,發現EB病毒潛伏期膜蛋白LMP1具有抑制DUSP6及DUSP8之能力。進而以shRNA方法證明LMP1的確參與EB病毒抑制DUSP6及DUSP8之過程。並且,LMP1可能藉由其C端活化區域CTAR1或CTAR2活化ERK訊息傳遞路徑,抑制DUSP6及DUSP8之表現。於細胞內訊息傳遞方面,LMP1可能藉由ERK同時抑制兩者DUSP之表現。此外,EB病毒活化Elk-1轉錄因子而使DUSP6表現量下降,但不影響DUSP8之表現量。利用螢光酵素報導基因分析顯示,LMP1可透過抑制DUSP6及DUSP8之啟動子藉以影響其基因表現,但可能透過不同之轉錄因子調控。 進一步,欲瞭解DUSP6及DUSP8在EB病毒感染宿主細胞中所扮演之生物角色及生理功能。發現LCLs以慢病毒方式轉導入DUSP6質體,使LCLs聚球型態變小,並且LCLs細胞數目也隨表現DUSP6而下降。進一步,欲探查表現DUSP6之LCLs命運為何,利用流式細胞儀分析細胞週期,發現大量表現DUSP6之LCLs細胞週期subG1百分比明顯增加。此外,也探查p-ERK、ERK、caspase及PARP表現量,於西方墨點法結果發現,ERK磷酸化程度降低,而caspase3及PARP有受到活化情形。以上結果顯示於LCLs表現DUSP6促使細胞凋亡。 並且,當DUSP6催化區域突變,則無法導致上述現象。 另一方面,DUSP8大量表現於LCLs中同樣造成LCLs聚球變小,細胞週期停留於subG1比率增加。然而,DUSP8促使細胞凋亡機制與DUSP6不同。當大量表現DUSP8於LCLs,p38磷酸化程度下降,卻不活化caspase3,而活化Bcl-2及PUMA。然而,DUSP8催化區域突變型對於細胞增生之影響仍尚未有進一步結果。 總結以上,EB病毒不朽化初級B細胞過程中,透過LMP1抑制DUSP6及DUSP8表現,因而防止細胞凋亡。 | zh_TW |
dc.description.abstract | Epstein-Barr virus (EBV) belongs to human Herpesviridae family. This virus is first virus defined by WHO as a human oncogenic virus. In vitro, EBV can immortalize primary B cells into lymphoblastoid cell lines (LCLs). Many studies evidence that EBV is associated with many human malignancies, such as Burkitt’s lymphoma, Hodgkin’s lymphoma, Post-transplant lymphoproliferative disorder, nasopharyngeal carcinoma etc and so on.
In order to persistent in host cells, EBV activate downstream signaling transduction pathway, such as NF-kB, ERK, JNK, p38, Akt, to induce host cell constitutive proliferation, and to prevent host cell from program cell death. Most importantly, EBV manipulates the host immune response so that it can escape the immune surveillance and persist in host cells. Previously, we utilized cDNA microarray to compare the whole panel of cellular gene expression between CD19+ primary B cells and LCLs which immortalized with B95.8 strain EBV. Preliminarily, we found that EBV influences the gene expression of many kinds of dual specificity phosphatase (DUSP), such as DUSP1, DUSP2, DUSP6 and DUSP8. One of the major functions for DUSP is to negatively regulate MAPK activities by dephosphorylaion of MAPK and inactivate their kinase activities. So, we wonder the expression and regulation of MAPK during the EBV immortalization process. According to their substract specificity, we selected 13 DUSPs to test their kinetic mRNA expression by RT-PCR. Among them, we saw the DUSP1, 2, 6, and 8 are obviously down-regulated when primary B cells become LCLs. Among them, we chose the DUSP6 and 8 as our study targets. In further Western blotting assay, the protein expression of both DUSP6 and 8 are also decreased. To further confirm these phenomena, four pairs of primary B cells and LCLs are detected for their protein expression of DUSP6 and 8. Next, we would like to know which viral gene is involved in these down-regulation effects. According to the results of lentiviral infection, the EBV latent membrane protein 1(LMP1) is responsible for this down-regulation. These results were both seen in Akata and BJAB cell lines. Furthermore, we show that LMP1 is necessary for DUSP 6 and 8 downregulation by shRNA approach. C-terminal activation domain (CTAR)1 and CTAR2 of LMP1 were required for this downregulation. In signaling, LMP1-mediated ERK pathway was involved in both DUSP-downregulation. In addition, ERK-downstream Elk1 was required for DUSP6 but not DUSP8 down-regulation. Based on the results of luciferase reporter assay, we demonstrated that LMP1 downregualtes DUSP6 and DUSP8 through inhibiting their promoter activity, but probably with different transcriptional factors. Of note, we desired to address the influence of this down-regulation. LCL clumping morphology was shrinking upon the DUSP 6-expressive lentivirus were transducted into LCLs. Consistently, the cell number were decreased during lentivirus infection. To clarify the question what is fate of DUSP6-overexpressive LCLs, we checked the cell cycle by flowcytometry. The sub-G1 population was obviously increased after over-expression. Meanwhile, we examined the expression of p-ERK, ERK, caspase and PARP. Obviously, Western-blotting data indicated that the amounts of p-ERK are decreased, while cleaved caspase 3 and cleaved PARP are increased. All the results hinted that over-expression DUSP 6 can cause cell apoptosis. Of note, the kinase mutated DUSP 6 would not trigger the above phenomena. In the case of DUSP8, the LCL clumping was also shrinking and the sub-G1 population was also increased. However, their apoptotic mechanism is different form over-expression DUSP6. During over-expression of DUSP8, p38 was decreased but caspase 3 kept the same. On the other hand, cleaved Bcl-2 and PUMA were increased. However, the kinase dead DUSP 8 did not cause any change for cell proliferation. So, we conclude that DUSP6 and DUSP8 are downregulated during EBV immortalization since LMP1 should prevent their effect from apoptosis. | en |
dc.description.provenance | Made available in DSpace on 2021-05-15T17:50:51Z (GMT). No. of bitstreams: 1 ntu-103-R01445122-1.pdf: 4519054 bytes, checksum: 406ebf9fde8b5b9ebcb9d101092563c1 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 摘要 I
Abstract III 序論 1 研究目的 12 材料與方法 13 結果 34 討論 43 圖 49 表 81 附錄 85 參考文獻 93 | |
dc.language.iso | zh-TW | |
dc.title | 雙特異性去磷酸酶6及8於EB病毒感染之調控與生物功能 | zh_TW |
dc.title | Regulation and Biological Functions of DUSP6 and DUSP8 in Epstein-Barr viral infection | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林素珍(Sue-Jane Lin),李明學(Ming-Hsueh Lee) | |
dc.subject.keyword | EB病毒,MAPKs,雙特異性磷酸?,LMP1, | zh_TW |
dc.subject.keyword | Epstein-Barr virus,MAPKs,Dual specificity phosphatase (DUSPs),LMP1, | en |
dc.relation.page | 102 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2014-08-19 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf | 4.41 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。